APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Apimeds Pharmaceuticals US, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.50−0.54 (-13.37%)
Close on Oct 19, 2026
- Market cap
- $6.00M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$14.90 (−80.98%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $6.00M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.06
- Dividend yield
- –
- Free cash flow yield
- -222.32%
Fundamentals
- Net income
- -$58.17M
- EPS, diluted
- -$36.69
- Free cash flow
- -$13.33M
- Book value per share
- $62.13
- Diluted shares
- 2M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$27.35M
Net income
-$58.17M
EPS, diluted
-$36.69
Free cash flow
-$13.33M
Reported periodTrailing twelve months